

Genomtec has filed a second patent application for the OncoSNAAT oncology project

Genomtec SA, a leading molecular diagnostics company headquartered in Wrocław (WSE ticker: GMT), announced today that it has filed a patent application with the British Patent Office for an innovative technology for the diagnosis of single-nucleotide genetic changes. The Company's strategy includes extending patent protection under the international PCT procedure.

"The OncoSNAAT project is progressing according to schedule, bringing us closer to creating an innovative diagnostic solution supporting oncological treatment and other applications in diagnostics. The method of detecting single-nucleotide genetic changes using isothermal amplification of nucleic acids, which we have applied for a patent for, combined with the earlier solution for the diagnosis of multi-nucleotide changes, creates a comprehensive diagnostic tool. It enables the detection of genetic variants that are key for the selection of therapy in oncology (CDx), with the potential for use in other areas of diagnostics. Filing the second patent application is a milestone in the development of our oncological project. The introduction of this technology can significantly increase the effectiveness of genetic diagnostics, which opens up new therapeutic possibilities for patients. Moreover, the potential of this method goes far beyond medicine," said Miron Tokarski, CEO of Genomtec SA

The methodology developed by Genomtec uses modified SNAAT/LAMP technology, which enables precise diagnosis of single-nucleotide genetic changes, especially in mixtures containing both mutated and non-mutated material. This technique finds application in oncology, including in the analysis of samples using liquid biopsy technology, as well as in other fields, such as veterinary medicine or food safety. This technology enables comprehensive diagnosis of genetic changes that are of key clinical importance, including in the selection of oncological therapies. In the Company's opinion, obtaining patent protection will strengthen its position in the M&A process.

About Genomtec:

Genomtec is a MedTech company specializing in developing advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows for fast and precise molecular analysis outside the laboratory environment without the need to engage qualified laboratory personnel. The solution uses microfluidic technology and proprietary, patented, isothermal SNAAT® technology. Genomtec technology is protected by 12 patents, including in Europe, the USA and Japan, and the Company has 35 patent applications pending.

The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections



The company's headquarters is located in Wrocław. Genomtec also has a branch in Great Britain, where part of the international research and engineering team is located.

More information is available on the company's website: www.genomtec.com

Media contact:

Michał Wierzchowski

Tel.: +48 531 613 067

michal.wierzchowski@ccgroup.pl

Contact for investors:

Agata Dzieciółowska

Tel.: +48 606 205 119

agata.dzieciolowska@ccgroup.pl